Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 17/05/19 at 11:09am

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate lawsuits accused them and others of suppressing competition. While Gilead had sought to retain dominance in the HIV drugs market, Teva was alleged to be at the centre of a conspiracy through which generic drugmakers divided up the market for generic meds.

On the other hand, are top story covered Novartis exec Jerome Moreau’s move to Mundipharma as he took on the role of Head of Access at the firm. Talking of access, NHS England agreed to pay for Biogen’s incredibly expensive SMA treatment Spinraza – sold in the US for $750,000 a year. For all of this and more, check out this week’s top ten on!

10. Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion

Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss firm Novartis in a deal worth as much as $5.3 billion.

9. Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel

Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for FDA approval by the US agency’s Oncologic Drugs Advisory Committee (ODAC), but another of its products was turned down.

8. Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says

Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for HIV drugs, according to a lawsuit filed by AIDS activists and unions.

7. NHS England agree to pay for Biogen's $750,000 a year SMA treatment Spinraza

NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza.

6. Clinical trial will test long acting HIV injection

A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV.

5. Eli Lilly's Emgality shows positive Phase 3 results in treatment of migraine

Eli Lilly has announced positive results from the Phase 3 EVOLVE-1 and EVOLVE-2 trials looking into Emgality (galcanezumab-gnlm) for the treatment of episodic migraine.

4. US States allege 20 generic drugmakers fixed prices of generic drugs

Forty-four US States have filed a lawsuit against 20 generic drugmakers – including Teva Pharmaceuticals – over allegations the firms fixed prices and stifled competition for generic meds.

3. FDA to end controversial "alternative summary reporting" of medical devices in bid to boost transparency

The FDA has revealed that it plans to terminate its "alternative summary reporting" programme which has allowed the manufacturers of medical devices to keep undesirable reports of malfunctions and adverse events out of public knowledge.

2. The interplay between the GDPR and the EU Clinical Trials Regulation

Paul Kavanagh, partner at law firm Dechert, explores the relationship between GDPR and CTR, and its potential impact on the legal implications of personal clinical trial data processing and handling.

1. Ex-GSK, Novartis exec named as Mundipharma's Head of Access

Mundipharma has announced that Jerome Moreau has joined the company as its new Head of Market Access.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches